Sponsors (2)
Introduced July 29, 2025 by Margaret Wood Hassan · Last progress July 29, 2025
The bill modernizes evidence and testing pathways for OTC topical drugs and sunscreens—bringing clearer guidance, transparency, and potential for faster, kinder testing methods—while creating tradeoffs in safety uncertainty, regulatory workload, possible price or delay impacts, and risks of public confusion or politicization.
Small manufacturers, researchers, hospitals, and consumers get clearer, standardized regulatory guidance and a predictable pathway for using non-animal tests and real‑world evidence when FDA evaluates OTC topical drugs and sunscreens.
Children, outdoor workers, uninsured individuals, and other sunscreen users retain better protection because the rulemaking must account for historical safety data and the public-health role of broad‑spectrum (SPF ≥15) sunscreens.
Patients (including people with chronic conditions and disabilities) may gain faster access to effective OTC topical medicines because the bill allows FDA to consider validated non‑animal testing methods and real‑world evidence to supplement traditional clinical data.
Patients and consumers face increased risk that some OTC topical products could be approved with less certain safety or effectiveness data if reliance on real‑world evidence and alternative, nonclinical methods proves insufficient.
The bill creates additional administrative and post‑market oversight costs for FDA and taxpayers and may divert agency staff time from other regulatory priorities.
Requiring the agency to incorporate historical data and new testing standards could delay finalization of sunscreen rules and slow availability of new sunscreen ingredients or formulations.
Based on analysis of 4 sections of legislative text.
Directs FDA to accept real‑world evidence and certain non‑animal testing approaches for nonprescription topical drugs, requires guidance and reporting, and applies these standards to sunscreen reviews.
Directs the FDA to adopt clearer, flexible evidence and testing standards for active ingredients in nonprescription topical drugs (including sunscreens). It requires FDA to accept real‑world evidence alongside traditional clinical trials, to consider nonclinical non‑animal testing approaches, to issue guidance on using those alternatives within one year, and to ensure a pending sunscreen administrative order uses these standards and recognizes historical safety data and the role of broad‑spectrum SPF 15+ sunscreens. The Department of Health and Human Services must report to Congress on implementation and publish annual updates for five years.